Can you tell me what is going on to expand the indications and approval of the
anti-VEGF drugs so that there is full Medicare and insurance coverage. Lucentis and Macugen are only FDA-approved for wet AMD, yet these drugs are useful in many other retinal inflammatory conditions, often the only treatment available for these problems, yet insurance won't pay.